Johnson & Johnson Announces Progress Toward Health for Humanity Goals
Johnson & Johnson today released its 2017 Health for Humanity Report, demonstrating its approach and the considerable progress it has made toward an ambitious social, environmental and governance commitment to advance the Company’s mission to drive better health for all.
Looking across all Johnson & Johnson’s business practices, the Company shares important disclosures about how it supports good health for patients, consumers, employees and local communities on a global scale. The report tracks how Johnson & Johnson is striving to eradicate and prevent disease, reimagine how care is delivered, and put a healthy mind, body and environment within reach of all people around the world.
The following reflect 2017 highlights:
Maintaining our commitment to eradicating and preventing disease
- Announced the U.S. FDA approval for JULUCA®(dolutegravir and rilpivirine) in November. Developed in collaboration with ViiV Healthcare, JULUCA® is the first and only complete, single-pill, two-drug regimen to treat HIV-1 infection.
- Expanded access to a cumulative 37,000 patients in 95 countries for MDR-TB therapy with SIRTURO® (bedaquiline) to better meet patients’ needs for new drugs globally. 
Reimagining how care is delivered
- Introduced GenH, a new global social venture to bring ideas from more than 54 countries, harness the power of innovators and entrepreneurs to design locally-tailored and globally-relevant solutions for enduring health, and offer mentorship and financial prizes to establish those ventures in countries such as India, Ghana, and Brazil.
- Reached broad expansion of mMitra, a groundbreaking mobile-messaging program in India that sends vital health information to expectant and new moms living in low-income urban communities. The program has been cited by the World Health Organization and others as a global example of a scaled digital health program.
Promoting lifelong health and wellbeing, and environmental health
- Introduced a new global standard for Parental Leave, where employees across the globe - including countries like Brazil, China, India and Japan - are eligible to take a minimum of eight weeks paid parental leave for birth or adoption.
- Reached 25% electricity use from renewable energy sources across the company and achieved Johnson & Johnson’s first-ever carbon-neutral status for our site in Helsingborg, Sweden for all energy sources across manufacturing, R&D and warehouse facilities. 
To watch a short video-summary of achievements in 2017, click here.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities, and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
 Assured by third-party, ERM Certification and Verification Services Inc.; figures are cumulative for 2016-2017 and have been rounded.
 Assured by third-party, ERM Certification and Verification Services Inc, for the period of 1 March 2017 to 31 December 2017